Tailoring of chronic lymphatic leukemia therapy

about

Tailoring of chronic lymphatic leukemia therapy

Item

http://www.wikidata.org/entity/Q37127542

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tailoring of chronic lymphatic leukemia therapy

@en

Tailoring of chronic lymphatic leukemia therapy.

@nl

type

Item

label

Tailoring of chronic lymphatic leukemia therapy

@en

Tailoring of chronic lymphatic leukemia therapy.

@nl

prefLabel

Tailoring of chronic lymphatic leukemia therapy

@en

Tailoring of chronic lymphatic leukemia therapy.

@nl

P1476

Tailoring of chronic lymphatic leukemia therapy

@en

P2093

Ashraf M Elhefni

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

Disease-specific biomarker discovery by aptamers.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

P304

201-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23997983

http://www.w3.org/2001/XMLSchema#string

P932

3755525

http://www.w3.org/2001/XMLSchema#string